Adherium Ltd. · ASX:ADR
Adherium — Investor Presentation (October 2022)
11 slides from Adherium's investor presentation, Oct 21, 2022
Slide 1: Leading respiratory eHealth
Leading respiratory eHealth 21 October 2022
Slide 2: Disclaimer and Forward-Looking Statement
DISCLAIMER AND FORWARD-LOOKING STATEMENT The material contained herein is of a general nature & has only been These risks & uncertainties include, but are not limited to: prepared as a presentation aid. This presentation does NOT contain all of i. the possible delays in & the outcome of product deve
Slide 3: Adherium is improving health outcomes in chronic respiratory disease
Adherium is improving health outcomes in chronic respiratory disease through world- leading remote patient monitoring technology and data ©Adherium 2022
Slide 4: Unmet Need: Significant Burden to Health Systems and Respiratory Patients
UNMET NEED: SIGNIFICANT BURDEN TO HEALTH SYSTEMS AND RESPIRATORY PATIENTS FROM PREVENTABLE GAPS IN INHALER TECHNIQUE AND ADHERENCE COPD THIRD UP TO 92% OF PREVENTABLE 80% OF LEADING CAUSE ASTHMA PATIENTS HOSPITALIZATION ASTHMA-RELATED OF DEATH USE THEIR COST US HEALTH HOSPITALIZATIONS GLOBALLY INHAL
Slide 5: Our Solution – The Hailie Platform
HAILIE PORTAL & OUR SOLUTION – THE HAILIE PLATFORM HAILIE SENSOR Compatible today with 91% of SDK/API the US top 20 inhaler Captures data for patient medication brands by sales management, digital volume. health records, clinical reference and enables SETS NEW PREVENTATIVE Only US FDA 510(k) cleared
Slide 6: A Flexible Channel Partner Platform
A FLEXIBLE CHANNEL PARTNER PLATFORM PROFESSIONAL PORTALS PATIENT TOOLS Health Care Professional Hailie App Population Health CLINICAL Dashboard ECOSYSTEM Adherium Health Data Hailie Digital Device Family Electronic Health Record 3rd Party App RestAPI Patient Management with Hailie Software Developme
Slide 7: Hailie Sensor Portfolio with US FDA 510(k) Clearances
HAILIE SENSOR PORTFOLIO WITH US FDA 510(k) CLEARANCES New, next generation sensors with physiological data capability for Anoro® Ellipta® / Arnuity® Ellipta® / for Symbicort® HFA Breo® Ellipta® / for Bevespi Aerosphere® Incruse® Ellipta® / Trelegy ® Ellipta® for Ventolin® HFA for Advair® HFA for Flo
Slide 8: Time is Now for Remote Patient Monitoring: Adherium Perfectly Placed
TIME IS NOW FOR REMOTE PATIENT MONITORING: ADHERIUM PERFECTLY PLACED Financial incentives for US doctors, hospital systems, medical groups • Two new US reimbursement codes for doctors to get paid: • Remote Physiological Monitoring (for respiratory flow rate) published 2019 • Remote Therapeutic Monit
Slide 9: Revenue by Generating and Transmitting Patient Data and Insights
REVENUE BY GENERATING AND TRANSMITTING PATIENT DATA AND INSIGHTS US ASTHMA AND COPD PATIENTS TOTAL ADDRESSABLE 51 M MARKET ADHERIUM TARGET REVENUE MODEL ➢ SaaS AND DATA FEES 8.5 M SERVICEABLE MARKET (SEVERE/DIFFICULT ➢ US$15-30/MO/PATIENT TO TREAT) ➢ GENERATING AND TRANSMITTING PATIENT DATA ~ 80 k M
Slide 10: Partner of Choice: An Accelerated Growth Strategy
PARTNER OF CHOICE: AN ACCELERATED GROWTH STRATEGY NOW: DELIVERING ON PRODUCT NEXT: FOCUS ON RECURRING REMOTE FUTURE: DEVELOP DATA INSIGHTS DEVELOPMENT MILESTONES PATIENT MONITORING REVENUE AND DATA SCIENCE PORTFOLIO Expand platform with new, next-generation Establish new commercial partnerships Acqu
Slide 11: References and data links available upon request
References and data links available upon request Confidential ©Adherium 2022 11